Rates of Ocular Adverse Events after Intravitreal Faricimab Injections

Based on one-year experience with faricimab in a large retina-only practice, our study identified a 1.9% rate of serious ocular adverse events and a similarly low rate of intraocular inflammation that was comparable to clinical trials.